Journal article

TAK-637. Takeda.

JB Furness

Current Opinion in Investigational Drugs | Published : 2001

Abstract

Abbott and Takeda are developing TAK-637, an orally active NK1 antagonist, for the potential treatment of urinary incontinence, depression, irritable bowel syndrome and pollakiuria. By November 1999, it was in phase II trials in Europe and phase I in Japan and the US for urinary incontinence [348496], [350686]. By October 2000, phase II trials had been initiated in the US for urinary incontinence, depression and IBS [381167], [386950], [419868], and in May 2001, these were scheduled to finish in 2002 [412024].

University of Melbourne Researchers